ArticleInflammopharmacology2026
Synergistic modulation of nociceptive and inflammatory pain by palmitoylethanolamide and Cucumis sativus extract in a monosodium-iodoacetate induced osteoarthritic rat model.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoarthritis (OA) is a progressive degenerative joint disease characterized by chronic inflammation, cartilage degradation, and persistent pain, leading to functional disability and reduced quality of life. Current pharmacological treatments, particularly non-steroidal anti-inflammatory drugs (NSAIDs), provide symptomatic relief but are associated with significant adverse effects during long-term use. The present study evaluated the therapeutic efficacy and pharmacological synergy of a novel combination formulation, Ostizeel™, comprising palmitoylethanolamide (PEA) and Cucumis sativus extract (CSE), in a monosodium iodoacetate (MIA)-induced rat model of osteoarthritis.
methodsForty-two female Wistar rats were randomized into seven experimental groups and treated orally with PEA, CSE, an NSAID standard, or their combinations for 28 days. Nociceptive behavior and functional recovery were assessed using movement-evoked pain scoring, Randall-Selitto mechanical hyperalgesia, von Frey allodynia testing, and dynamic weight-bearing analysis. Systemic inflammation and cartilage catabolism were evaluated by measuring serum interleukin-1β (IL-1β) and matrix metalloproteinase-13 (MMP-13) levels. Drug-drug interaction was assessed using the Bliss Independence model and a combination index derived from the Loewe additivity principle.
resultsThe combination treatment significantly improved pain thresholds and limb function compared with either monotherapy (p < 0.0001). Serum IL-1β and MMP-13 levels were reduced by approximately 50%, indicating potent anti-inflammatory and chondroprotective effects. Bliss Independence analysis yielded positive synergy scores across behavioural and biochemical endpoints, suggesting that the observed combination effects exceeded predicted additive responses.
conclusionSynergistic modulation of nociceptive and inflammatory pathways were demonstrated by PEA and CSE, which highlight Ostizeel™ as a promising pharmacological strategy for osteoarthritis management.
Indexed as
Identifiers
41945007What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.